315 related articles for article (PubMed ID: 17069061)
21. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
[TBL] [Abstract][Full Text] [Related]
22. [The study on the assessment of the new levodopa drug--stalevo (levodopa/carbidopa/entacapone), in treatment of Parkinson's disease in out-patient clinical practice (the results of the open START-M)].
Boĭko AN; Batysheva TT; Minaeva NG; Babina LA; Vdovichenko TV; Zhuravleva EIu; Shikhkerimov RK; Malykhina EA; Khozova AA; Zaĭtsev KA; Kostenko EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(12):21-4. PubMed ID: 18427455
[TBL] [Abstract][Full Text] [Related]
23. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
[TBL] [Abstract][Full Text] [Related]
24. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
Fernandez HH; Standaert DG; Hauser RA; Lang AE; Fung VS; Klostermann F; Lew MF; Odin P; Steiger M; Yakupov EZ; Chouinard S; Suchowersky O; Dubow J; Hall CM; Chatamra K; Robieson WZ; Benesh JA; Espay AJ
Mov Disord; 2015 Apr; 30(4):500-9. PubMed ID: 25545465
[TBL] [Abstract][Full Text] [Related]
25. Should levodopa dose be reduced when switched to stalevo?
Linazasoro G; Kulisevsky J; Hernández B;
Eur J Neurol; 2008 Mar; 15(3):257-61. PubMed ID: 18215153
[TBL] [Abstract][Full Text] [Related]
26. Stalevo for Parkinson's disease.
Med Lett Drugs Ther; 2004 May; 46(1182):39-40. PubMed ID: 15136772
[No Abstract] [Full Text] [Related]
27. [Levodopa medications in the treatment of Parkinson's disease].
Fedorova NV; Iablonskaia AIu; Bel'gusheva ME
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(5):30-6. PubMed ID: 21666590
[TBL] [Abstract][Full Text] [Related]
28. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
Reichmann H; Emre M
Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
30. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
Stocchi F; Hsu A; Khanna S; Ellenbogen A; Mahler A; Liang G; Dillmann U; Rubens R; Kell S; Gupta S
Parkinsonism Relat Disord; 2014 Dec; 20(12):1335-40. PubMed ID: 25306200
[TBL] [Abstract][Full Text] [Related]
31. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
Müller T; Ander L; Kolf K; Woitalla D; Muhlack S
J Neural Transm (Vienna); 2007; 114(11):1457-62. PubMed ID: 17564755
[TBL] [Abstract][Full Text] [Related]
32. [Treatment for advanced Parkinson's disease with intestinal levodopa/carbidopa gel: review of efficacy and safety].
Timofeeva AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):145-51. PubMed ID: 25629138
[TBL] [Abstract][Full Text] [Related]
33. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
Silver DE
Expert Rev Neurother; 2004 Jul; 4(4):589-99. PubMed ID: 15853578
[TBL] [Abstract][Full Text] [Related]
34. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
35. Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study).
Myllylä V; Haapaniemi T; Kaakkola S; Kinnunen E; Hartikainen P; Nuutinen J; Rissanen A; Kuopio AM; Jolma T; Satomaa O; Heikkinen H
Acta Neurol Scand; 2006 Sep; 114(3):181-6. PubMed ID: 16911346
[TBL] [Abstract][Full Text] [Related]
36. [The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease].
Kovács N; Aschermann Z; Ács P; Bosnyák E; Deli G; Janszky J; Komoly S
Ideggyogy Sz; 2014 Jul; 67(7-8):245-50. PubMed ID: 25509365
[TBL] [Abstract][Full Text] [Related]
37. Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
Muhlack S; Herrmann L; Salmen S; Müller T
J Neural Transm (Vienna); 2014 Nov; 121(11):1357-66. PubMed ID: 24770794
[TBL] [Abstract][Full Text] [Related]
38. Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.
Simonson W; Hauser RA; Schapira AH
Ann Pharmacother; 2007 Nov; 41(11):1842-9. PubMed ID: 17878397
[TBL] [Abstract][Full Text] [Related]
39. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
Fernandez HH; Odin P
Curr Med Res Opin; 2011 May; 27(5):907-19. PubMed ID: 21351823
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
Müller T
Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
